Abstract: Examples herein involve designating a first dimension of a thread visualization based on timing of a duration of a user action, the user action corresponding to a user interaction with an application; designating a second dimension of the thread visualization based on a number of threads of the application utilized for running tasks in response to the user action, the second dimension comprising a number of parallel timelines corresponding to the number of threads; determining locations for representations of the tasks within the appropriate parallel timelines of the thread visualization based on the timing of the tasks and the threads running the tasks; and rendering the thread visualization on a display.

Abstract: A system for connecting user action flows is disclosed. The system determines when a first object is created on a first thread in response to a first user action. Additionally, the system stores a first relationship between the first thread and the first object based on the determination of when the first object is created. Moreover, the system determines when the first object is running on a second thread that differs from the first thread, and stores a second relationship between the second thread and the first object based on the determination of when the first object is running.

Abstract: Examples herein involve designating a first dimension of a thread visualization based on timing of a duration of a user action, the user action corresponding to a user interaction with an application; designating a second dimension of the thread visualization based on a number of threads of the application utilized for running tasks in response to the user action, the second dimension comprising a number of parallel timelines corresponding to the number of threads; determining locations for representations of the tasks within the appropriate parallel timelines of the thread visualization based on the timing of the tasks and the threads running the tasks; and rendering the thread visualization on a display.

Abstract: In one implementation, a system for user action duration includes a monitor engine to monitor a number of async operations to be loaded on a user interface, a detection engine to determine a repeating async operation from the number of async operations that has a pattern of repeating timeouts, a removal engine to remove the repeating async operation from the number of async operations, and a calculation engine to calculate a total time for the remaining number of async operations based on a total timeout of each of the remaining number of async operations.

Abstract: Example implementations relate to connecting user action flows. Some implementations may determine when a first object is created on a first thread in response to a first user action. Additionally, some implementations may store a first relationship between the first thread and the first object based on the determination of when the first object is created. Moreover, some implementations may determine when the first object is run on a second thread that differs from the first thread, and may store a second relationship between the second thread and the first object based on the determination of when the first object is run.

Abstract: Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making anybodies to myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.

Abstract: Disclosed is the novel myokine known as myonectin (CTRP15) an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making anybodies to myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.

Abstract: In one implementation, a system for user action duration includes a monitor engine to monitor a number of async operations to be loaded on a user interface, a detection engine to determine a repeating async operation from the number of async operations that has a pattern of repeating timeouts, a removal engine to remove the repeating async operation from the number of async operations, and a calculation engine to calculate a total time for the remaining number of async operations based on a total timeout of each of the remaining number of async operations.

Abstract: Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.

Abstract: Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.